MX9501193A - Formulaciones de oxibutinina de liberacion controlada. - Google Patents

Formulaciones de oxibutinina de liberacion controlada.

Info

Publication number
MX9501193A
MX9501193A MX9501193A MX9501193A MX9501193A MX 9501193 A MX9501193 A MX 9501193A MX 9501193 A MX9501193 A MX 9501193A MX 9501193 A MX9501193 A MX 9501193A MX 9501193 A MX9501193 A MX 9501193A
Authority
MX
Mexico
Prior art keywords
controlled release
release oxybutynin
oxybutynin formulations
sustained release
formulations
Prior art date
Application number
MX9501193A
Other languages
English (en)
Other versions
MXPA95001193A (es
Inventor
Anand R Baichwal
Original Assignee
Mendell Co Inc Edward
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22766272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9501193(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mendell Co Inc Edward filed Critical Mendell Co Inc Edward
Publication of MX9501193A publication Critical patent/MX9501193A/es
Publication of MXPA95001193A publication Critical patent/MXPA95001193A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La presente invencion describe una formulacion de oxibutinina de liberacion sostenida oral solida que incluye una matriz de liberacion sostenida que incluye un agente formador de gel, un diluyente farmacéutico inerte y un agente de entrelazamiento cationico.
MXPA/A/1995/001193A 1994-03-04 1995-03-03 Formulaciones de oxibutinina de liberacioncontrolada MXPA95001193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08206416 1994-03-04
US08/206,416 US5399359A (en) 1994-03-04 1994-03-04 Controlled release oxybutynin formulations

Publications (2)

Publication Number Publication Date
MX9501193A true MX9501193A (es) 1998-07-31
MXPA95001193A MXPA95001193A (es) 1998-11-09

Family

ID=

Also Published As

Publication number Publication date
WO1995023593A1 (en) 1995-09-08
HUT72981A (en) 1996-06-28
FI113337B (fi) 2004-04-15
HU9503054D0 (en) 1996-01-29
CN1111404C (zh) 2003-06-18
ES2180574T3 (es) 2003-02-16
JPH09501445A (ja) 1997-02-10
EP0700284B1 (en) 2002-08-28
DE69431247T2 (de) 2003-01-02
FI955215A0 (fi) 1995-11-01
FI955215A (fi) 1995-11-01
DE69431247D1 (de) 2002-10-02
US5399359A (en) 1995-03-21
AU676556B2 (en) 1997-03-13
JP2005126444A (ja) 2005-05-19
CN1111507A (zh) 1995-11-15
CA2161103A1 (en) 1995-09-08
ATE222753T1 (de) 2002-09-15
PT700284E (pt) 2003-01-31
DK0700284T3 (da) 2003-01-06
IL112637A0 (en) 1995-05-26
EP0700284A4 (en) 1996-11-06
CA2161103C (en) 1999-12-07
IL112637A (en) 1999-01-26
AU6588894A (en) 1995-09-18
EP0700284A1 (en) 1996-03-13
JP3699117B2 (ja) 2005-09-28

Similar Documents

Publication Publication Date Title
HU9503054D0 (en) Controlled release oxybutynin formulations
CA2171844A1 (en) Sustained release formulations for 24 hour release of metoprolol
CA2164619A1 (en) Once-a-day metoprolol oral dosage form
AU550992B2 (en) Sustained release diethylpropion comppositions
MX9704910A (es) Formula de liberacion controlada (albuterol).
CA2131350A1 (en) Sustained release drug formulation containing a tramadol salt
AU5022593A (en) Prodrugs, their preparation and use as pharmaceuticals
AUPM969994A0 (en) Equine anthelmintic formulations
AU6569694A (en) Active substance-containing plaster
CA2164513A1 (en) Sustained release excipient
AU1932997A (en) Dosage forms and uses
AU1230800A (en) Controlled delivery of antidepressants
AU3908795A (en) Equine anthelmintic formulations
CA2249637A1 (en) Uniform drug delivery therapy

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: TELEFLEX GFI CONTROL SYSTEMS L.P.

MM Annulment or lapse due to non-payment of fees